Single-chain antibodies: A therapeutic modality for cancer gene therapy (review).
Single-chain antibodies: A therapeutic modality for cancer gene therapy (review).
复制标题
DOI：
10.3892/ijo.24.4.765
复制
发表时间：
2004-04
影响因子：
5.2
通讯作者：
C. Leath;J. T. Douglas;D. Curiel;R. Alvarez
中科院分区：
文献类型：
--
作者：
C. Leath;J. T. Douglas;D. Curiel;R. Alvarez
基因治疗已迅速发展成为一个不仅可以治疗先天性代谢缺陷的领域，还可以治疗与不良结果相关的其他疾病，例如恶性肿瘤，其中瞬时基因表达可以起到治疗作用。癌症基因治疗是一种新的治疗形式，利用正常细胞和恶性细胞之间分子水平的差异。目前正在评估的基因治疗方法包括使用具有复制能力的病毒、突变补偿策略、改进肿瘤特异性启动子的靶向性以及使用增强感染性病毒。基因治疗的另一个方面在过去几年中引起了越来越多的兴趣，那就是单链抗体（scFv）的利用。具体来说，scFv 已被用来靶向与癌发生相关的分子过程，并提高基因转移效率。我们将限制讨论 scFv 在靶向与癌发生相关的分子过程中的作用。
Gene therapy has rapidly evolved into a field that is treating not only inborn errors of metabolism, but other diseases associated with poor outcomes such as malignancy, where transient gene expression can be therapeutic. Cancer gene therapy is a novel form of treatment that exploits differences at the molecular level between normal and malignant cells. Current gene therapy approaches that are being evaluated include the use of replication competent viruses, mutation compensation strategies, improved targeting with tumor specific promoters, and the utilization of enhanced infectivity viruses. An additional aspect of gene therapy that has gained increased interest in the last several years is the utilization of single-chain antibodies (scFv). Specifically, scFv have been utilized to target molecular processes associated with carcinogenesis, as well as to improve gene transfer efficiency. We will limit our discussion to the role of scFv in targeting molecular processes associated with carcinogenesis.